The efficacy of different doses of decitabine sequential low-dose chemotherapy on acute myeloid leukemia
CAI Sheng-xin
WANG Li-hua
XING Li-na
ZHANG Xiao-lei
LI Yang
GUO Xiao-ling
GUO Xiao-nan
REN Jin-hai
Abstract：Objective To compare the efficacies of different doses of decitabine sequential low-dose chemotherapies in the treatment of acute myeloid leukemia ( AML) . Methods A retrospective analysis of 65 patients with AML treated with different doses of decitabine sequential low-dose chemotherapies was performed. All patients were divided into Group A ( 20 mg /m2 × 5 d) and Group B ( 20 mg /m2 × 3 d) . The remission rate of the two groups was compared. Results In the Group A, 32 of 37 patients had complete remission, the complete remission rate was 86. 5％. In the Group B, 18 of 28 patients had complete remission, and the complete remission rate was 64. 3％. The difference between the two groups was statistically significant ( P =0. 035) . Compared group A with group B, the median durations of platelet< 20 × 109·L-1 and leukocytes < 0. 5 × 109·L-1 were no significant difference ( P > 0. 05) . Other treatment-related adverse events in patients of groups A and B were predominantly infections ( pulmonary infections and bloodstream infections). Other adverse reactions were more frequent with fatigue, constipation, loss of appetite. Infections of these patients were controlled by anti-infective therapy. There were no deaths in both groups, and there was no significant difference in adverse reactions between the two groups ( P > 0. 05) . Conclusion In the treatment of AML, decitabine 20 mg /m2 × 5 days sequential low-dose chemotherapy may be better.
Keywords：decitabinedifferent dosesacute myeloid leukemiachemotherapy
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 612-614,617 )